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Microtubule associated protein tau (MAPT) is involved in the pathogenesis of Alzheimer’s
disease and many forms of frontotemporal dementia (FTD). We recently reported that
Aβ-mediated inhibition of hippocampal long-term potentiation (LTP) in mice requires
tau. Here, we asked whether expression of human MAPT can restore Aβ-mediated
inhibition on a mouse Tau−/− background and whether human tau with an FTD-causing
mutation (N296H) can interfere with Aβ-mediated inhibition of LTP. We used transgenic
mouse lines each expressing the full human MAPT locus using bacterial artificial
chromosome technology. These lines expressed all six human tau protein isoforms on
a Tau−/− background. We found that the human wild-type MAPT H1 locus was able
to restore Aβ42-mediated impairment of LTP. In contrast, Aβ42 did not reduce LTP in
slices in two independently generated transgenic lines expressing tau protein with the
mutation N296H associated with frontotemporal dementia (FTD). Basal phosphorylation
of tau measured as the ratio of AT8/Tau5 immunoreactivity was significantly reduced in
N296H mutant hippocampal slices. Our data show that human MAPT is able to restore
Aβ42-mediated inhibition of LTP in Tau
−/− mice. These results provide further evidence
that tau protein is central to Aβ-induced LTP impairment and provide a valuable tool for
further analysis of the links between Aβ, human tau and impairment of synaptic function.
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INTRODUCTION
Multiple lines of evidence indicate an interaction between amyloid-beta (Aβ) and tau protein
in Alzheimer’s disease, and tau protein is required for the effect of Aβ in many experimental
paradigms. Thus, cultured neurons from tau knockout (Tau−/−) mice are not susceptible to
Aβ-induced synaptic damage and neurotoxicity (Rapoport et al., 2002; Nussbaum et al., 2012;
Zempel et al., 2013) or to Aβ-induced defects in axonal transport (Vossel et al., 2011). Reducing
tau levels prevents Aβ-induced cognitive deficits and premature mortality, reduces spontaneous
and induced seizure activity, and prevents synaptic impairment in mutant APP-expressing mouse
models (Roberson et al., 2007, 2011). Furthermore, Aβ plays a permissive role for the spread of
tau pathology in vivo (Pooler et al., 2015). Similarly, tau oligomers produce an acute inhibition of
hippocampal LTP and memory (Fá et al., 2016), and inhibition of the tau kinases CDK5 or GSK-3β
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reduces Aβ-induced neuronal cell death and malfunction
(Llorens-Marítin et al., 2014) suggesting that abnormal tau
mediates some of the effects of Aβ.
Previous reports consistently show that Aβ inhibits long-
term potentiation (LTP) in the hippocampus (Ondrejcak et al.,
2010), a widely accepted cellular model for learning and memory
(Bliss and Collingridge, 1993), and we have previously shown
that hippocampal slices from Tau−/− animals are not susceptible
to human Aβ42-mediated LTP impairment (Shipton et al.,
2011). Furthermore, our work and that of others have shown
that inhibition of GSK-3β prevents LTP impairment following
exposure to Aβ and prevents Aβ-mediated increase in tau
phosphorylation at disease-relevant AT8 epitopes (Jo et al., 2011;
Shipton et al., 2011). To further analyse the interaction of Aβ42
and human tau and build upon our previous work, here we
asked whether expressing the human tau protein in mice on
a Tau−/− background (Dawson et al., 2001) can restore the
Aβ42-mediated inhibition of LTP. For this, we studied transgenic
mice expressing one of two variants of the human tau protein:
either a wild type form, or a mutant form carrying the disease-
associated mutation, N296H, known to lead to frontotemporal
dementia (FTD; Iseki et al., 2001). Both transgenes contain the
complete MAPT genomic locus, which allows for the study
of aberrant splicing, a phenomenon which has been observed
in a variety of FTDs and tauopathies (Spillantini et al., 1998;
Takanashi et al., 2002). The N296H mutation, in particular, is
a splice site mutation that affects the isoform ratio detected in
the insoluble fraction of tau fragments obtained from patient
brains (Iseki et al., 2001) leading to an increase in tau isoforms
harboring four microtubule-binding repeats (4R). Like many
other familial FTD mutations (Denk and Wade-Martins, 2009),
N296H causes increased inclusion of MAPT exon 10, leading
to an overrepresentation of tau isoforms with four microtubule-
binding repeats, known as 4R tau (Grover et al., 2002; Yoshida
et al., 2002).
We hypothesized that the expression of wild type human
tau would restore the inhibitory effect of Aβ42 on synaptic
plasticity in Tau−/− mice. Further, we tested whether mutant
N296H tau would either occlude or prevent the Aβ42-mediated
inhibition of hippocampal LTP. Elucidating the extent to which
normal or mutant human tau protein can restore Aβ42-mediated
inhibition of LTP in Tau−/− mice should further enhance our
understanding of the interaction between Aβ42 and tau protein
in synapse dysfunction.
MATERIALS AND METHODS
Ethical Statement
Animal care and experimental procedures were conducted in
accordance with UK Home Office regulations under the Animals
(Scientific Procedures) Act of 1986. The work was carried out
under PPL 30/2757 and all efforts were made to optimize the
number of animals used.
Transgenic MAPT Mice
Mice were generated using bacterial artificial chromosome (BAC)
technology to express the 143 kb MAPT locus (Supplementary
Methods) in mice with a genetic knock-out of endogenous tau
(Tau−/−; Dawson et al., 2001) on a C57/BL6-J background.
This allowed the physiological expression of all human tau
isoforms. We chose to express the more common H1 haplotype
given its association with increased risk of Alzheimer’s disease.
Mice expressed either MAPT-H1 or the same transgene with
the point mutation N296H. Two lines of N296H P1-derived
artificial chromosome (PAC) transgenic mice (N24 and N51)
were generated to control for insertion effects. Samples for
analysis of tau isoform expression with Western blot were
subjected to alkaline phosphatase treatment (Lambda protein
phosphatase NEV, 4,000 U per 80 µg lysate) and assessed with
the human specific Tau-13 antibody (1:5000 Abcam). Both male
and female mice were used in each experiment.
RNA In situ Hybridization
In situ hybridization for transgene expression was carried out
on frozen 14 µm thick tissue sections using a DIG-labeled
LNA probe (Exiqon) designed to be specific for human MAPT
(5′ DIG-gctcagccatcctggttcaaa-DIG 3′). Hybridisation and signal
detection were carried out as previously described (Jefferson and
Volpi, 2010).
Exon 10 Splicing Measurements
Quantitative analysis of exon 10 splice ratios was obtained
using the SequenomMassARRAY Platform. Briefly, RT-PCR was
performed to amplify exon 4 through to exon 11 of the MAPT
gene. Sequenom analysis was performed by the Wellcome Trust
Centre for Human Genetics, Oxford, to determine the relative
amount of exon 10 inclusion vs. exclusion using mass-assisted
laser desorption/ionization—time of flight (MALDI-TOF). Each
MALDI-TOF assay was repeated eight times in both forward and
reverse direction, and N = 2–3 mice were tested per group. A
control construct expressing a known 1:1 ratio of 4R:3R tau was
used for normalization.
Slice Preparation and Pharmacology
Following the procedure described in Shipton et al. (2011),
parasagittal hippocampal slices (400 µm) were prepared after
decapitation under deep isoflurane-induced anesthesia. After
dissection in ice-cold artificial CSF (ACSF) containing (in mM)
126 NaCl, 3 KCl, 1.25 NaH2PO4, 2 MgSO4, 2 CaCl2, 25 NaHCO3,
10 glucose, pH 7.2–7.4, bubbled with carbogen gas (95% O2,
5% CO2), slices were maintained at room temperature (22–
25◦C) in a submerged-style holding chamber for at least 1 h and
after that incubated in ACSF with or without freshly prepared
220 nM human Aβ42 (also referred to as Aβ1–42 Tocris, UK)
in a submerged chamber for 1–3 h (Shipton et al., 2011; Um
et al., 2012). Perfusion with a half-concentration of the drug
continued after slices were transferred to the interface chamber
for fEPSP recordings under the assumption that this reduction
to 110 nM would not cause a washout of the Aβ42 effect on
plasticity. LTP was induced with high frequency stimulation
using a single 1 s long 100 Hz induction protocol. Mice used for
electrophysiology were 4–7 months old. The electrophysiology
data were obtained from 18 H1 mice, 15 N51 mice, and 6 N24
mice, Number of observations (N) represents the number of
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slices subject to each pharmacological treatment. Input-output,
paired pulse and LTP data were obtained from the same slices.
Only slices with a stable baseline (drift < 10%) were used for
LTP induction. A sample of concentrated Aβ42 (44 µM) was
processed in the same way as above and collected at the time
of LTP measurement for protein stain analysis (Supplementary
Methods) to verify the presence of oligomeric Aβ assemblies in
the solution (Supplementary Figure 1).
Data Analysis
Data were analyzed with one- or two-way ANOVAwith genotype
and treatment as independent variables. Data are represented as
means ± SEM. Unless otherwise stated, post-hoc comparisons
were corrected using Dunnett’s method with H1 ACSF data as
control.
To establish whether significant levels of LTP were obtained
within each experimental group we performed a paired Student’s
t-test comparing baseline synaptic strength with synaptic
strength at 40 ± 2.5 min post-HFS per individual experimental
condition.
Western Blot
For analysis of slices incubated with or without addition of 220
nM Aβ42, following 1 h recovery at room temperature in ACSF,
slices from 6 to 7 month old mice (N = 6 mice) were incubated
for 2 h in either Aβ42 or control solutions. Slices were then
snap frozen and collected for western blot analysis (Additional
information in Supplementary Methods). Slices from the same
mouse and treatment were pooled together resulting in N = 1
per mouse per treatment. AT8 and Tau-5 immunoreactivity was
first normalized to GADPH. Immunoreactivity for both H1 and
N51 was normalized to baseline H1 levels.
RESULTS
Following our previous observation that early LTP in mice with
a genetic knock out of tau protein (Tau−/−) is not affected by
Aβ, we wanted to investigate whether transgenic expression of
human tau (MAPT) genes would allow normal LTP on a Tau−/−
background in mice and permit LTP inhibition by Aβ42.
We used three transgenicmouse lines. The first line carried the
transgenic locus of wild-type human tau (line H1), and we used
two independent lines carrying the tau N296H mutation linked
to FTD with parkinsonism (lines N51 and N24). To identify
the six tau isoforms we performed Western blot following a
dephosphorylation treatment (Figure 1A) using a human tau
specific antibody.
We wanted to test the effect of expressing tau protein on
hippocampal LTP; to confirm that human tau mRNA was
expressed in the hippocampus we used in situ hybridisation. We
observed an enrichment of our signal in the hippocampal cell
body layers (Figure 1B) in a pattern similar to that observed
in the Allen brain atlas for adult mouse tau (Allen Institute for
Brain Science, 2015). To test whether expression of normal or
mutant human tau caused changes at the mRNA expression level
we measured the ratio of exon10 inclusion vs. exon10 exclusion
in mRNA transcripts and we found that MAPT-N296H had a
significantly higher inclusion of exon 10 (Line H1 0.30± 0.005N
= 3, N296H—line 24—0.78± 0.02 N = 2, P < 0.05, Figure 1C).
To test synaptic function and LTP in hippocampal CA3-CA1
synapses we obtained acute brain slices from these transgenic
mice. We incubated slices in either 220 nM oligomeric Aβ42
(Supplementary Figure 1) or control ACSF for 1–3 h.
We have previously shown that basal synaptic transmission
is not affected following acute Aβ42 incubation in WT or
Tau−/− mice. To measure input-output relation, we evoked
field excitatory postsynaptic potentials (fEPSPs) in CA1 with
extracellular stimulation of Schaffer collaterals by delivering
brief electrical pulses of increasing amplitude from 20 to
200 µA. We observed similar input-output curves for both
ACSF and Aβ42 treatment in all three transgenic lines tested
(Figures 2A–C). Repeated measures ANOVA between-subjects
showed no significant effect of genotype [F(2, 68) = 0.33, P
= 0.72] or treatment [F(1, 68) = 0.74, P = 0.39] and no
genotype∗treatment interaction [F(2, 68) = 0.51, P = 0.49].
To characterize paired-pulse ratio as a measure of presynaptic
function, we delivered paired stimuli 40 ms apart at CA3-CA1
synapses (Figure 2D). Two-way ANOVA on paired-pulse data
showed no effect of genotype [F(2, 82) = 1.67, P = 0.19] or
treatment [F(1, 82) = 0.06, P = 0.81] and no genotype
∗treatment
interaction [F(2, 82) = 0.02, P = 0.98].
LTP in the hippocampus is widely assumed to be a cellular
correlate of learning and memory. We previously showed that
220 nM Aβ42 inhibits tetanus-induced LTP in wild type mice
and that it does not have an effect on LTP in Tau−/− mice
(Shipton et al., 2011). We wanted to test whether transgenic
expression of human tau restored the effect of Aβ42 on LTP
in mice on a Tau−/− background; for this we used mice with
transgenic expression of tau in its wild type form (line H1) or
with a point mutation related to FTD (N296H, lines N24 and
N51). To analyse the effects of Aβ42 on LTP wemonitored fEPSPs
by stimulating Schaffer collaterals and induced LTP with tetanic
(HFS) stimulation (Figures 2E–G).
We found significant LTP following HFS in H1 mice (148.43
± 5.47, N = 16, P < 1 × 10−8 compared to baseline) and,
interestingly, also normal LTP levels in both lines expressing
tau with the N296H mutation (line N51 149.82 ± 7.40, N =
18, P < 1 × 10−6, line N24 144.32 ± 5.80, N = 7, P < 1 ×
10−5). We hypothesized that in H1 mice, incubation of acute
slices with Aβ42 peptide would significantly impair hippocampal
LTP owing to the wild type human tau expression. Furthermore,
we wanted to test the effects of human tau with the N296H
mutation on LTP under control conditions and following Aβ42
incubation. Following from pilot experiments on WT slices
demonstrating an inhibitory effect of Aβ42 on LTP as described
in Shipton et al. (2011) (not shown), we interleaved control and
Aβ42 incubation experiments and compared the resulting LTP
for the three transgenic lines with and without Aβ42. Following
a two-way ANOVA analysis of LTP results, we found an effect
of genotype F(2, 84) = 3.11, P < 0.05 on the induction of LTP
and although no effect of treatment on LTP was observed F(1, 84)
= 0.82, P = 0.37, importantly a genotype∗treatment interaction
was found F(2, 84) = 2.83, P < 0.05. fEPSP slopes in H1 slices
with Aβ42 incubation were significantly different from baseline
Frontiers in Neuroscience | www.frontiersin.org 3 April 2017 | Volume 11 | Article 201
Vargas-Caballero et al. Human Tau, Amyloid-Beta and LTP
FIGURE 1 | Six isoforms of human tau protein in transgenic mouse lines MAPT-H1, and MAPT-N296H expressed in a mouse Tau−/− (Mapt−/−)
background. (A) Western blot with a human-specific tau antibody. MAPT-H1 and MAPT-N296H transgenic animals expressed all six isoforms of the human tau
protein. (B) RNA in situ hybridization analyzing expression of MAPT in the hippocampus of Tau−/− and MAPT mice. (C) Quantitative analysis of splice ratios of MAPT
exon 10+(4R)/exon 10−(3R) RNA transcript in the brains from H1 and N296H (line N24) mice showing an enhanced ratio of exon 10 inclusion in N296H mice,
*p < 0.05.
FIGURE 2 | Hippocampal LTP in slices from mice expressing human tau on a Tau−/− background is impaired by Aβ42, however Aβ42 does not reduce
LTP in slices from mice expressing tau protein N296H associated with FTD. Field recordings from CA3 to CA1 synapses in control ACSF (black) or after
incubation with Aβ42 (red). (A–C) Synaptic input-output curves corresponding to genotypes above graph. (D) Paired-pulse data. (E–G) LTP in wild type human tau
(H1) and two transgenic lines (N51, N24) expressing mutant tau (N296H). LTP was induced by delivering a high-frequency stimulation (HFS) train (100 Hz for 1 s). The
insets show superimposed example traces before and 40 min after HFS for each condition. Scale bars: 5 ms/0.5 mV. (H) Summary of LTP results 40 min after HFS,
*P < 0.05.
following HFS (LTP following Aβ42 incubation: 124.7 ± 6.2,
N = 18, P < 1 × 10−4), however, post-hoc comparison between
H1 in control conditions and H1 following incubation in Aβ42
revealed a significant difference between these treatments (P <
0.05, Figure 2H). Strikingly, there was no difference in LTP when
comparing control and Aβ42 conditions in the N51 line with the
N296H mutation (Aβ42 LTP, 153.6 ± 6.1, N = 20, P = 0.65
compared to control). These results showing no effect of Aβ42
on LTP in line N51 N296H mice are further supported by our
data analyzing line N24, an independently generated line with the
N296H mutation to control for transgene insertion effects. This
line also showed normal LTP following Aβ42 incubation (Aβ42
LTP = 147.3 ± 6.3, N = 6, P = 0.50 compared to control levels,
Figure 2H).
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In contrast to N296H mice, Aβ42 significantly inhibited LTP
in H1 mice. We have previously shown that tau phosphorylation
measured with AT8 immunoreactivity was increased following
incubation with Aβ42 in hippocampal slices from WT mice
(Shipton et al., 2011). In order to investigate whether an increase
in tau phosphorylation is associated with Aβ42-mediated LTP
impairment, we assessed total tau levels and tau phosphorylation
levels in acute slices from H1 and N296H mouse hippocampal
slices. We first noted that in control samples total tau levels
normalized to GAPDH were 5.4 ± 0.3 times higher in N51
animals compared to H1 values normalized to GAPDH (N =
6 H1, N = 6 N51, P < 1 × 10−5. Figures 3A,B). However,
phosphorylated tau measured with the AT8 antibody as a
proportion of total tau measured with the Tau5 antibody with
Western blot was significantly reduced in N51 hippocampal slices
in control ACSF conditions compared to H1 mice (0.43± 0.03 of
normalized values from H1 mice,N = 6 H1,N = 6 N51, P < 1×
10−5, Figure 3B).
We wanted to test whether a significant increase in
phosphorylation would be observed in either H1 or N51 mouse
hippocampus following incubation with Aβ42 as we previously
reported in WT mice, and whether this could be prevented by
using the specific GSK3 inhibitor AR-A014418 (Bhat et al., 2003).
For this we normalized AT8/Tau5 level following Aβ42 or Aβ42 +
AR-A014418 incubation to basal AT8/Tau5 levels as an internal
control for each genotype. Two way ANOVA revealed an effect
of genotype [F(1, 32) = 5.27, P < 0.05], however we did not
see a main effect of treatment [F(2, 32) = 2, P = 0.15]. Post-hoc
comparison of AT8/Tau5 ratios in control conditions betweenH1
and N296H resulted in a significant difference [H1 1.3 ± 0.2 (N
= 6), N51 0.8 ± 0.1 (N = 6), P < 0.05], however, neither H1 nor
N51 AT8/Tau5 ratio following Aβ42 incubation was significantly
higher than normalized control levels within the same genotype
(H1 P = 0.10; N51 P = 0.96; Figure 3C).
DISCUSSION
We have shown that wild type human tau is able to restore Aβ42-
mediated inhibition of LTP measured in mouse hippocampal
slices on a mouse Tau−/− background. However, brain slices
from transgenic mice expressing a version of tau protein with a
point mutation associated with familial FTD (N296H, line N51)
showed normal LTP both under control conditions and following
Aβ42 incubation. We also assessed a second independently-
derived mouse line expressing all six tau isoforms of N296H
mutant tau (line N24) corroborating a mutation-dependent
resistance to Aβ42-induced inhibition of LTP. Our data suggest
that the N296H mutant tau acts like a functional knockout in the
pathways that link Aβ42 to LTP impairment, since N296H mice
like Tau−/− mice are protected from the effects of Aβ42 peptide
on LTP.
The bacterial chromosome transgenic technology we used
for generation of transgenic animals allows for anatomical
expression patterns at physiological levels, however it is not
possible to match exact level of protein expression in all
transgenic lines. We measured protein expression levels in H1
and N51 mice, with H1 mice showing lower levels of tau protein.
In all three lines we were able to observe the six tau isoforms
produced by alternative splicing from the human tau locus. Wild
type human tau in H1mice was able to restore the Aβ42-mediated
phenotype on a Tau−/− background, indicating sufficient protein
levels to link Aβ42 with synaptic plasticity dysfunction. In N296H
mice we observed normal basal levels of synaptic transmission
and normal LTP. If N296H tau protein caused a gain of toxic
function, a stronger phenotype would be expected (Roberson
et al., 2007) from higher expression levels in line N296H-N51.
However, we did not observe an enhanced effect under basal
or Aβ42 conditions in slices with the N296H mutation and we
therefore argue that expression levels did not confound our data.
We assessed phosphorylation levels of tau protein with the
AT8 antibody compared to total levels of tau with the Tau5
antibody in H1 and N51 mice. A comparison of H1 and N51
lines showed that at basal levels the ratio of AT8 to Tau5
immunoreactivity was much higher in H1 hippocampi, however,
these levels were not associated with dysfunction, as previously
reported in WT mice (Shipton et al., 2011; Morris et al., 2015).
We also did not observe tau aggregates in the H1 or N296H
lines following AT8 immunohistochemistry in slices from up
to 21 month old mice (data not shown). This is in contrast to
a previously reported mouse line expressing the H1 haplotype
under a P1-derived artificial chromosome with high expression
levels on a Tau−/− background, which showed abnormal tau
hyperphosphorylation from 3 months of age (Andorfer et al.,
2003).
The AT8 phosphorylation levels, synaptic input-output
curves, paired-pulse ratios, and hippocampal LTP data presented
here are comparable to our previous data from wild type and
Tau−/− mice (Shipton et al., 2011). Following our previous
published observations and the electrophysiological recordings
presented here we hypothesized that AT8 immunoreactivity
would increase in H1 hippocampal slices incubated with Aβ42
compared to control conditions associated with inhibition of
LTP. However, owing to low protein expression levels in H1 mice
we had high variability in ourWestern blot analysis. Although we
observed a trend of increased phosphorylation levels in H1 slices
following Aβ42 incubation consistent with our previous findings,
the results did not reach significance. It may be necessary to
express H1 in homozygosity to yield a stronger phenotype for
molecular analyses of tau phosphorylation and downstream
events.
N51 mice expressing N296H mutant human tau, despite
showing higher expression levels than H1 mice, showed starkly
decreased levels of tau phosphorylation and were not susceptible
to an Aβ42-induced increase in tau phosphorylation at the
AT8 site. However, while these findings are congruent with
a loss of function via a reduction in basal and Aβ42-induced
tau phosphorylation, it is possible that the mutation, either in
addition to or independent of its effects on tau phosphorylation,
could lead to other changes in tau, such as other post-
translational modifications. These could play a distinct role in the
Aβ42 effects on hippocampal LTP that we do not rule out here.
There is mounting evidence for tau as a downstreammediator
of Aβ effects (Rapoport et al., 2002; Roberson et al., 2007, 2011;
Shipton et al., 2011; Vossel et al., 2011), however, the mechanisms
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FIGURE 3 | Tau protein phosphorylation measured as AT8 to Tau5 immunoreactivity ratio is lower for N296H hippocampal slices compared to H1.
(A) Example Western blots showing immunoreactivity to AT8 (phosphorylated tau) and Tau5 (total tau) in slices from MAPT-H1 and MAPT-N256H (line N51) mice
incubated in control conditions, with Aβ42, or with Aβ42 + GSK3 inhibitor. (B) Quantification of phosphorylated (AT8) tau (top), total (Tau5) tau (middle)
immunoreactivity relative to housekeeping protein GAPDH for both strains, and quantification of AT8/Tau5 immunoreactivity ratio (bottom) for both strains in basal
conditions (untreated slices) for N = 6 mice each. (C) Quantification of AT8/Tau5 immunoreactivity ratio in control conditions and following Aβ42 or Aβ42 + GSK3
inhibitor incubation for N = 6 mice, each normalized to basal levels in each genotype *P < 0.05.
by which tau mediates neuronal Aβ42-mediated dysfunction
remains poorly understood. There is strong evidence that small
soluble oligomers formed by phosphorylated forms of tau are
highly toxic, however, it is unclear whether their early effects
are driven by alterations in the cytoskeleton structure (Cowan
and Mudher, 2013), by promoting downstream pathological
cascades (De Strooper and Karran, 2016) or a combination of
these. One potential set of mechanisms whereby the absence of
functional tau in hippocampal neurons (i.e., Tau−/− or MAPT-
N296H) could prevent the effect of amyloid beta on LTP is by
modifying the cellular distribution of fyn kinase. Under normal
conditions the physical tau/fyn association results in targeting of
fyn kinase to postsynaptic sites (Ittner et al., 2010) leading to basal
phosphorylation of synaptic NMDARs at Y1472 by fyn which is
notably reduced in Tau−/− mice (Ittner et al., 2010). Aβ42 drives
tau phosphorylation at GSK3β epitopes (Jo et al., 2011; Shipton
et al., 2011; Mondragon-Rodriguez et al., 2012) by a variety of
proposedmechanisms in theWnt signaling pathway (Purro et al.,
2012; Vargas et al., 2014). This tau phosphorylation results in
enhanced dendritic fyn localization coupled to a disruption of
the PSD-95/NMDAR interaction (Mondragon-Rodriguez et al.,
2012) and abnormal postsynaptic density ultrastructure (Purro
et al., 2012). The relationship between Aβ42-mediated disruption
in glutamate uptake (Li et al., 2011) and tau phosphorylation
is unclear, however this dysregulation has been reported to
occur on the same time scale as in our present experiments
and is well-placed to feed-back into the mechanism of Aβ42-
mediated synaptic dysregulation on the time scale of hours. This
suggests that the mechanisms described above could provide
the basis of acute Aβ42-mediated LTP dysfunction. Here we
show that normal but not mutant MAPT-N296H can restore
Aβ42-mediated LTP dysfunction in H1 but not N296H mice.
Our Western blot analysis demonstrates that MAPT-N296H
is hypophosphorylated under basal conditions and that its
phosphorylation measured at the AT8 epitope does not change
following Aβ42 incubation in contrast to the phosphorylation
increase observed inMAPT-H1 hippocampal slices. This suggests
that the uncoupling of Aβ42 effects on LTP by MAPT-N296H
occurs at the level of tau phosphorylation which could feed
directly into the formation of small soluble tau oligomers
(Cowan et al., 2010). This strengthens the link between Aβ42
signaling, tau phosphorylation at GSK3 epitope (detected by
AT8 immunoreactivity) and LTP impairment observed in WT
but not Tau−/− mice (Shipton et al., 2011). Nevertheless, our
experiments do not address whether theMAPT-N296Hmutation
in tau affects its association with fyn or its subcellular localization.
The mechanisms by which FTD-related mutations lead to
neuronal dysfunction and loss are not well understood. However,
there is evidence that distinct tau gain or loss of function
mutations or progranulin mutations (in the absence of tau
mutations) can lead to FTD (Baker et al., 2006; De Silva
et al., 2006). Our results indicate that the N296H mutation in
MAPT leads to hypophosphorylation and to a loss of function
in the mechanisms that link Aβ42 with impairment of LTP.
Therefore, the mechanism that causes neuronal dysfunction
in N296H mutant cells may differ from that leading to tau
hyperphosphorylation and downstream mechanisms in AD. We
suggest that the human tau transgenic models we present here—
whereby wild type H1 human tau mediates Aβ42-inhibition of
LTP and N296H does not—can be used to further explore Aβ42-
tau interactions in disease.
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